DAIICHI SANKYO COMPANY, LIMITED Logo

DAIICHI SANKYO COMPANY, LIMITED

A global healthcare company that researches and develops novel pharmaceutical solutions.

4568 | T

Overview

Corporate Details

ISIN(s):
JP3475350009
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目5番1号

Description

Daiichi Sankyo is an innovative global healthcare company focused on the research, development, and delivery of pharmaceutical solutions. By leveraging cutting-edge science, technology, and data analytics, the company develops novel medicines and medical treatments to address unmet needs. Its core mission is to contribute to the enrichment of quality of life for patients worldwide. The company maintains a robust R&D pipeline and actively engages in open innovation to advance its therapeutic offerings, with a significant focus on oncology and specialty medicines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-09 01:30
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.3 KB
2025-11-07 05:22
確認書
Japanese 8.2 KB
2025-11-07 05:19
半期報告書-第21期(2025/04/01-2026/03/31)
Japanese 321.7 KB
2025-10-10 02:55
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-10-03 04:15
発行登録追補書類(株券、社債券等)
Japanese 130.8 KB
2025-09-05 03:06
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.3 KB
2025-08-07 05:49
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2025-07-17 02:04
発行登録書(株券、社債券等)
Japanese 24.8 KB
2025-07-09 02:32
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-06-24 06:02
訂正発行登録書
Japanese 8.9 KB
2025-06-24 05:36
臨時報告書
Japanese 25.7 KB
2025-06-23 08:40
訂正発行登録書
Japanese 8.9 KB
2025-06-23 07:44
臨時報告書
Japanese 31.3 KB
2025-06-20 07:20
内部統制報告書-第20期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-20 07:20
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all DAIICHI SANKYO COMPANY, LIMITED filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DAIICHI SANKYO COMPANY, LIMITED

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DAIICHI SANKYO COMPANY, LIMITED via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.